Circio, formerly known as Targovax, is a clinical-stage immuno-oncology company developing immune activators to target solid tumors.

Circio's mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines.

Circio was founded in 2010 as Targovax, and has rebranded to Circio in Apr 2023. The company is headquartered in Oslo, Norway, with an office in Helsinki, Finland.

Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. Circio's proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. 

Circio's circAde, is the only currently known circRNA program targeting solid tumors. Circio´s clinical immunotherapy programs are designed to activate the patient´s own immune system to fight cancer cells and provide benefit to patients with no or few treatment alternatives.

Circio’s second clinical stage program is an immunotherapy targeting KRAS driver mutations. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway.

Circio is backed by Atlas Capital Markets, Innovation Norway, Birk Venture, Radium Hospital Research Foundation, Algot Invest, and Trygve Schiorbeck. The company has raised a total of $34M to date. Circio has also acquired Oncos Therapeutics in Jul 2015.